Год: 2020
Язык: Russian
Этот материал также есть на других языках: Арабский Английский Французский Испанский
Автор(ы): World Federation of Hemophilia
Формат: Видео
The currently evolving novel therapies for the management of hemophilia has ushered in a new era characterized by improved prophylaxis targets and outcomes.
In this session from the WFH 2020 Virtual Summit, Johnny Mahlangu, Victor Blanchette, Robert Klamroth and Emna Gouider redefine prophylaxis in the modern era by revisiting its definition, presenting data to support higher trough levels to achieve through prophylaxis, and introducing steady-state hemostasis as a possible new target for prophylaxis. The benefits of low-dose prophylaxis will also be discussed.
Click on the icon below to access more on-demand Virtual Summit recordings.
This WFH webinar was originally presented in English.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.
The previous edition of this resource has also been translated into the following languages, with permission from the WFH, by
Listen to this 2-hour webinar presented on July 27, 2021 to learn about global topics related to bleeding disorders. The
© 2025 World Federation of Hemophilia
